PHARMA SHOULD EN­COUR­AGE THE IN­TER­EST OF PHYSI­CIANS TO PAR­TIC­I­PATE IN CLIN­I­CAL TRI­ALS

BioSpectrum (India) - - COVER STORY -

In­dia is glob­ally rec­og­nized as an at­trac­tive des­ti­na­tion for con­duct­ing clin­i­cal tri­als ow­ing to its huge pa­tient pool, a tech­ni­cally com­pe­tent work­force and sig­nif­i­cant cost savings. How­ever, it ac­counts for less than 1.4% of global clin­i­cal tri­als at present. While the govern­ment is al­ready work­ing on the reg­u­la­tory en­vi­ron­ment to in­crease these num­bers, it will be equally im­por­tant to en­cour­age higher par­tic­i­pa­tion from the med­i­cal com­mu­nity.

Physi­cian-re­searchers play a huge role in im­prov­ing the qual­ity of both ser­vices and re­search stud­ies. In In­dia, the lin­guis­tic bar­rier is a ma­jor prob­lem for re­cruit­ing pa­tients and giv­ing them proper in­struc­tions and knowl­edge about tri­als. Hence, it is of ut­most im­por­tance for physi­cians from all across the coun­try to take part in clin­i­cal tri­als. Since a ma­jor­ity of tri­als are in­dus­try-spon­sored, it is cru­cial for pharma to ex­am­ine and elim­i­nate fac­tors that hold physi­cians back from be­ing ac­tively in­volved in reg­u­la­tory stud­ies.

Doc­plexus, a largest and fastest grow­ing on­line com­mu­nity for doc­tors of In­dia, con­ducted a sur­vey on 1105 doc­tors spe­cial­iz­ing in Phar­ma­col­ogy/Clin­i­cal Phar­ma­col­ogy, Gen­eral Medicine, Car­di­ol­ogy, Ortho­pe­dics, Neu­rol­ogy and Urol­ogy to un­der­stand their in­cli­na­tions and con­cerns re­gard­ing clin­i­cal tri­als in In­dia.

It re­vealed fol­low­ing key in­sights:

Doc­tors are in­ter­ested in clin­i­cal tri­als data

Doc­tors want to be up­dated on clin­i­cal prac­tices

Sev­eral bar­ri­ers re­strict physi­cians’ par­tic­i­pa­tion in clin­i­cal tri­als

Poor ac­cess to latest prac­tices is cre­at­ing mis­con­cep­tions

It is ev­i­dent that physi­cians ac­knowl­edge the huge role played by clin­i­cal tri­als in im­prov­ing health­care out­comes. Their par­tic­i­pa­tion will only in­crease as they get ad­e­quate fi­nan­cial as­sis­tance, pro­tected time for re­search, help with data man­age­ment and reg­u­lar up­dates on reg­u­la­tions and prac­tices.

KEY TAKE­AWAYS FOR PHARMA

Doc­tors track clin­i­cal tri­als data to gauge the preva­lence of dis­ease, stay up­dated on new mol­e­cules, and un­der­stand the role of eth­nic­ity in pa­tient’s re­spon­sive­ness to treat­ment.

Pharma should en­cour­age the in­ter­est of physi­cians to par­tic­i­pate in clin­i­cal tri­als by giv­ing them ad­e­quate fi­nan­cial as­sis­tance.

There should be a sys­tem or in­for­ma­tion por­tal in place to ed­u­cate and train the doc­tors about reg­u­la­tions and tri­als method­ol­ogy in clin­i­cal tri­als.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.